Our guiding light and principle. To us, honor is the necessary foundation for realizing our mission. Without honor, nothing else matters.
Natalie, 10, GRIN2B Patient
We are neuroscience innovators.
1. a keeper or custodian of a collection.
We aim to identify, acquire, and develop a collection of high-potential technologies addressing a broad range of neurological and psychiatric disorders and advance them through approval and commercialization. Our decisions to advance projects are based on fundamental analyses of the science, clinical data, regulatory path, commercial viability, and, above all else: our ability to serve patients and caregivers.
As a Blackstone Life Sciences portfolio company, Neurvati is powered by best-in-class expertise, relentless passion, and deep resources to optimize the development of neuroscience therapeutics. We engage hand-picked strategic partners to broaden our reach while aligning ourselves with patient communities to enhance the development of treatments capable of transforming the lives of patients.
We are creative partners.
Our business model is structured to meet the demands of neuroscience drug development and commercialization. We implement a long-term, strategic view of the entire neuroscience ecosystem to assemble and advance a collection of potentially transformative products. We establish fit-for-purpose subsidiary companies around product candidates to maximize business versatility and operational efficiency, supported and facilitated by our deep resource-base. This model enables us to advance a full spectrum of technologies to help patients who are counting on us to develop and commercialize novel products.
Neurvati’s first subsidiary company, GRIN Therapeutics, is developing an investigational product, radiprodil, as a novel therapy for patients diagnosed with GRIN-related disorders. GRIN-related disorders are genetically defined pediatric encephalopathies that present with a spectrum of symptoms, including epilepsy, behavioral disorders, autism, intellectual disability, and movement disorders. Radiprodil selectively targets receptors in the brain called NR2B receptors. NR2B receptors are overactive in the brains of GRIN2B-related disorder patients with gain-of-function mutations and are believed to drive many of the debilitating symptoms. By targeting the root cause of the disorder, we believe that radiprodil has potential to serve as a possible option for patients.
We are working closely with the GRIN-related disorders community to understand the community’s priorities. We are grateful to GRIN2B Foundation, GRIN2B Europe, GRIN Syndroom Netherlands, and CureGRIN for their partnership.
Meet our leadership team. We have deep subject matter expertise, extensive networks, and proven track records making the Neurvati team uniquely equipped to deliver on our mission.
Board of Directors
Backed by a financial investment from Blackstone, Neurvati Neurosciences is well-resourced to advance drug candidates through near and long term milestones. Operating under the Blackstone umbrella, our unique business model maximizes value creation of drug candidates and empowers the operational agility and clinical execution critical to sustainable, competitive success.
To learn more about our company, partnership opportunities, or if you want to say hello, get in touch with a member of the Neurvati team below.